Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Embryonal Rhabdomyosarcoma: later-stage trial registry

1 of 4 indexed Embryonal Rhabdomyosarcoma trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Embryonal Rhabdomyosarcoma: 4 US clinical trials tracked, 1 recruiting.

Embryonal Rhabdomyosarcoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 3 of these trials.

Enrollment posture brief

Registry condition embryonal-rhabdomyosarcoma

OPEN 1 | RECR 25% | LATE 3 | EARLY 0 | RANK #4115 | SPON 3

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Embryonal Rhabdomyosarco (th…25%
Open-enrollment share among volume-matched conditions near Embryonal Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Embryonal Rhabdomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Embryonal Rhabdomyosarcoma is recruiting below its size-band peers.

    1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 33

Phase Distribution

PhaseTrial count
Phase 3 3

Named interventions

Most-linked intervention names on Embryonal Rhabdomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dactinomycin Biological
2 trials
Questionnaire Administration Other
2 trials
Laboratory Biomarker Analysis Other
2 trials
Bone Scan Procedure
2 trials
Computed Tomography Procedure
2 trials
Biospecimen Collection Procedure
2 trials
Cyclophosphamide Drug
2 trials
Irinotecan Hydrochloride Drug
1 trials

US sites by state

Facility locations filed on Embryonal Rhabdomyosarcoma trials. A trial with sites in several states counts in each.

California 3 trials
Arizona 3 trials
Arkansas 3 trials
Alabama 3 trials
Alaska 2 trials
Pennsylvania 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Embryonal Rhabdomyosarcoma page

4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Embryonal Rhabdomyosarcoma condition card totals 4 registered trials; most-linked intervention Dactinomycin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.